The Role of Aldosteronism in Causing Obesity-Related Cardiovascular Risk

Cardiology Clinics

Volumn 28, Issue 3, 2010, Pages 517-527

  Calhoun, David A ^a   Sharma, Kumar ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adipocyte; Aldosterone; Eplerenone; Hypertension; Obesity; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; SPIRONOLACTONE;

ADIPOCYTE; ARTERIAL STIFFNESS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE COURSE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; LOW DRUG DOSE; OBESITY; PRIORITY JOURNAL; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; METABOLISM; PATHOPHYSIOLOGY; RISK FACTOR;

ADIPOCYTES; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; OBESITY; RISK FACTORS;

EID: 77954465954     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2010.04.001     Document Type: Review

References (60)

1. Ong K.L., Cheung B.M., Man Y.B., et al. Prevalence, awareness, treatment, and control of hypertension among United States Adults 1999-2004. Hypertension 2007, 49:69-75.
2. Garrison R.J., Kannel W.B., Stokes J., et al. Incidence and precursors of hypertension in young adults: the Framingham Off-spring Study. Prev Med 1987, 16:235-251.
3. Sharabi Y., Gotto I., Huerta M., et al. Susceptibility of the influence of weight on blood pressure in men versus women: lessons from a large-scale study of adults. Am J Hypertens 2004, 17:404-408.
4. Jones D.W., Kim J.S., Andrew M.E., et al. Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens 1994, 12:1433-1437.
5. Newton-Cheh C., Guo C.Y., Gona P., et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007, 49:846-856.
6. El-Gharbawy A.H., Nadig V.S., Kotchen J.M., et al. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 2001, 37:845-850.
7. Grim C.E., Cowley A.W., Hamet P., et al. Hyperaldosteronism and hypertension: ethnic differences. Hypertension 2005, 45:766-772.
8. Reynolds R.M., Walker B.R., Phillips D.I., et al. Programming of hypertension: associations of plasma aldosterone in adult men and women with birthweight, cortisol, and blood pressure. Hypertension 2009, 53:932-936.
9. Weinbereger M.H., Roniker B., Krause S.L., et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709-716.
10. Gordon R.D., Ziesak M.D., Tunny T.J., et al. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trail volunteers. Clin Exp Pharmacol Physiol 1993, 20:296-298.
11. Gordon R.D., Stowasser M., Tunyy T.J., et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315-318.
12. Rossi G.P., Bernini G., Caliumi C., et al. PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006, 48:2293-2300.
13. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892-896.
14. Gallay B.J., Ahmad S., Xu L., et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001, 37:699-705.
15. Eide I.K., Torjesen P.A., Drolsum A., et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004, 22:2217-2226.
16. Štrauch B., Zelinka T., Hampf M., et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003, 17:349-352.
17. Gaddam K.K., Nishizaka M.K., Pratt-Ubunama M.N., et al. Resistant hypertension characterized by increased aldosterone levels and persistent intravascular volume expansion. Arch Intern Med 2008, 168:1159-1164.
18. Nishizaka M.K., Zaman M.A., Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925-930.
19. Fox C.S., Larson M.G., Hwang S.J., et al. Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int 2006, 69:2064-2069.
20. Rossi G.P., Bernini G., Giovambattista D., et al. PAPY Study Investigators. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006, 48:232-238.
21. Bochud M., Nussberger J., Bovet P., et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006, 48:239-245.
22. Milliez P., Girerd X., Plouin P.F., et al. Evidence of an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243-1248.
23. Beygui F., Collet J.P., Benoliel J.J., et al. High plasma aldosterone levels on admission are associated with death in patient presenting with acute ST-elevation myocardial infarction. Circulation 2006, 114:2604-2610.
24. Epstein M., Williams G.H., Weinberger M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006, 1:940-951.
25. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
26. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
27. Rocha R., Stier C.T., Kifor I., et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871-3878.
28. Schiffrin E.L. Effects of aldosterone on the vasculature. Hypertension 2006, 47:312-318.
29. Zennaro M.C., Caprio M., Feve B. Mineralocorticoid receptors in the metabolic syndrome. Trends Endocrinol Metab 2009, 20:444-451.
30. Yokota K., Shibata H., Kurihara I., et al. Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J Biol Chem 2007, 282:1998-2010.
31. + transport in cortical collecting duct cells. J Am Soc Nephrol 2005, 16:2279-2287.
32. Ichimura T., Yamamura H., Sasamoto K., et al. 14-3-3 proteins modulate the expression of epithelial Na+ channels by phosphorylation-dependent interaction with Nedd4-2 ubiquitin ligase. J Biol Chem 2005, 280:13187-13194.
33. Kiyomoto H., Rafiq K., Mostofa M., et al. Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury. J Pharmacol Sci 2008, 108:399-405.
34. Ray P.E., Suga S., Liu X.H., et al. Chronic potassium depletion induces renal injury, salt sensitivity, and hypertension in young rats. Kidney Int 2001, 59:1850-1858.
35. Nakamura T., Kataoka K., Fukuda M., et al. Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis. Hypertension 2009, 54:544-551.
36. Lee S.H., Yoo T.H., Nam B.Y., et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol 2009, 297:F1381-F1390.
37. Xue C., Siragy H.M. Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 2005, 46:584-590.
38. Svenningsen P., Bistrup C., Friis U.G., et al. Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol 2009, 20:299-310.
39. Rocchini A.P., Katch V.L., Gerkin R., et al. Role of aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol 1986, 57:613-618.
40. Goodfriend T.L., Kelley D.E., Goodpaster B.H., et al. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 1999, 7:355-362.
41. Goodfriend T.L., Egan B.M., Kelley D.E. Plasma aldosterone, plasma lipoproteins, obesity and insulin in humans. Prostaglandins Leukot Essent Fatty Acids 1999, 60:401-405.
42. Andronico G., Cottone S., Mangano M.T., et al. Insulin, renin-aldosterone system and blood pressure in obese people. Int J Obes Relat Metab Disord 2001, 25:239-242.
43. Kidambi S., Kotchen J.M., Keishnaswami S., et al. Aldosterone contributes to blood pressure variance and to likelihood of hypertension in normal-weight and overweight African Americans. Am J Hypertens 2009, 22:1303-1308.
44. Mulè G., Nardi E., Cusimano P., et al. Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with metabolic syndrome. Am J Hypertens 2008, 21:1055-1061.
45. Rossi G.P., Belfiore A., Bernini G., et al. Body moss index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 2008, 93:2566-2571.
46. Tuck M.L., Sowers J., Dornfeld L., et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981, 304:930-933.
47. Engeli S., Böhnke J., Gorzelniak K., et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005, 45:356-362.
48. Dall'Asta C., Vedani P., Manunta P., et al. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutr Metab Cardiovasc Dis 2009, 19:110-114.
49. Nguyen A., Calmy A., Schiffer V., et al. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Med 2008, 9:142-150.
50. Lo J., Looby E.D., Wei J., et al. Increased aldosterone among HIV-infected women with visceral fat accumulation. AIDS 2009, 23:2366-2370.
51. Alvarez-Madrazo S., Padmanabhan S., Mayosi B.M., et al. Familial and phenotypic associations of the aldosterone renin ratio. J Clin Endocrinol Metab 2009, 94:4324-4333.
52. Khosla N., Kalaitzidis R., Bakris G.L. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009, 30:418-424.
53. de Souza F., Muxfeldt E., Fiszman R., et al. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010, 55:147-152.
54. Weiland F., Verspohl E.J. Local formation of angiotensin peptides with paracrine activity by adipocytes. J Pept Sci 2009, 15:767-776.
55. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
56. Engeli S., Schling P., Gorzelniak K., et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?. Int J Biochem Cell Biol 2003, 35:807-825.
57. Jeon J.H., Kim K.Y., Kim J., et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J 2008, 22:1502-1511.
58. Goodfriend T.L., Ball D.L., Egan B.M., et al. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004, 43:358-363.
59. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003, 100:14211-14216.
60. Krug A.W., Vleugels K., Schinner S., et al. Human adipocytes induce an ERK1/2 MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR) and angiotensin II-sensitization in human adrenocortical cells. Int J Obes (Lond) 2007, 31:1605-1616.